Table 1. Clinical data of 34 patients... | American Society of Hematology

Table 1.

Clinical data of 34 patients with follicular lymphoma and pretreatment circulating t(14;18)-positive cells

	n	%
Sex
Male	21	62
Female	13	38
Age
Median (y)	52
Range (y)	30-79
Ann Arbor stage
Stage II bulky or III	11	32
Stage IV	23	68
Systemic symptoms	7	21
Bulky disease	17	52
Bone marrow involvement^*	23	72
Leukemic	2	6
Previous wait-and-see policy
n	7	21
Median period (mo)	20
Range (mo)	9-32
Response to 8 CVP + IFN
Complete remission	16	44
Partial remission	11	34
Stable disease	2	6
Progressive disease	5	16
End of protocol treatment^†
Insufficient response to induction	7	29
Toxicity of induction	3	13
Progression during maintenance	9	37
Toxicity of maintenance	5	21

	n	%
Sex
Male	21	62
Female	13	38
Age
Median (y)	52
Range (y)	30-79
Ann Arbor stage
Stage II bulky or III	11	32
Stage IV	23	68
Systemic symptoms	7	21
Bulky disease	17	52
Bone marrow involvement^*	23	72
Leukemic	2	6
Previous wait-and-see policy
n	7	21
Median period (mo)	20
Range (mo)	9-32
Response to 8 CVP + IFN
Complete remission	16	44
Partial remission	11	34
Stable disease	2	6
Progressive disease	5	16
End of protocol treatment^†
Insufficient response to induction	7	29
Toxicity of induction	3	13
Progression during maintenance	9	37
Toxicity of maintenance	5	21

CVP indicates cyclophosphamide, vincristine, and prednisone courses; IFN, interferon alpha-2b.

Bone marrow examination performed in 32 of 34 patients.

24 of 34 patients ended treatment according to the protocol; others continued treatment.